Advanced glycation end products, galectin-3, matrix metalloproteinase-9 activity in men with heart failure and concomitant benign prostatic hyperplasia with androgen deficiency

V.S. Nedzvetsky; O.Yu.  Sirenko; V.A.  Tkachenko; O.V.  Kuryata

doi:10.26641/2307-0404.2021.4.248094

Authors

V.S. Nedzvetsky Bingol University, Selahaddin-i Eyyubi Mah. Üniversite Cad. No 1, Bingöl, 12000, Turkey https://orcid.org/0000-0001-7352-441X
O.Yu. Sirenko Dnipro State Medical University, V. Vernadskyi str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0003-4728-8614
V.A. Tkachenko Dnipro State Medical University, V. Vernadskyi str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0003-2231-2913
O.V. Kuryata Dnipro State Medical University, V. Vernadskyi str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-7642-0077

DOI:

https://doi.org/10.26641/2307-0404.2021.4.248094

Keywords:

heart failure, preserved ejection fraction, testosterone deficiency, advanced glycation end products

Abstract

The aim was to evaluate serum levels of matrix metalloproteinases-9 activity, advanced glycation end products, galectin-3, C-reactive protein in men with heart failure and benign prostatic hyperplasiawith testosterone deficiency. The testosterone level was determined by immune-enzyme analysis. The content of advanced glycation end products in plasma were analysed by quantitative autofluorescence. The metalloproteinases-9 activity was estimated with fluorometry. The level of galectin-3, C-reactive protein was determined by immune-enzyme analysis. 1^st group was made up by the men with heart failure and benign prostatic hyperplasia with testosterone deficiency; 2^nd group – by the men without testosterone deficiency. The men with heart failure and benign prostatic hyperplasia with testosterone deficiency had a significantly higher level of advanced glycation end products, galectin-3, matrix metalloproteinases-9 activity in comparison with men with heart failure without testosterone deficiency (p<0.001). Correlation relations between serum advanced glycation end products in patients of the main group with age, ejection fraction, testosterone level were determined – r=0.48 (p<0.001), r=-0.62 (p<0.001), r= -0.66 (p<0.001) respectively. Receiver operating characteristic analysis for predictive role in heart failure with preserved ejection fraction have shown high degree of sensitivity and specificity for advanced glycation end products in serum (p<0.001). Middle-aged men with heart failure with preserved ejection fraction and benign prostatic hyperplasia with testosterone deficiency are characterised by increased serum advanced glycation end products, galectin-3, matrix metalloproteinases-9 activity, C-reactive protein. Serum advanced glycation end products are potential biomarkers of development of heart failure with phenotype of preserved ejection fraction in this cohort.

References

Antomonov MYu. [Mathematical processing and analysis of biomedical data]. MITC "Medinform". 2018. p. 579. Russian.

Shevtsova AI, Gordienko YuA, Shaulska OE, Skoromna AS. inventor; DSMU, assignee. [Method for determination of gelatinazes in blood plasma]. Ukraine Patent 83196, No. u2013 03700. 2013 Aug 08. Ukrainian.

Juraj Koska, Aramesh Saremi, Scott Howell, Gideon Bahn, Barbora De Courten, Henry Ginsberg, Paul J. Beisswenger, Peter D. Reaven. Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care. 2018;41(3):570-6. doi: https://doi.org/10.2337/dc17-1740

Pinto-Junior DC, Silva KS, Michalani ML, et al. Advanced glycation end products-induced insulin resis¬tance involves repression of skeletal muscle GLUT4 expression. Sci Rep. 2018;8:8109. doi: https://doi.org/10.1038/s41598-018-26482-6

Chung CC, Hsu RC, Kao YH, Liou JP, Chen YJ. Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-β and angiotensin II signaling. Int. J. Cardiol. 2014;176:386-93. doi: https://doi.org/10.1016/j.ijcard.2014.07.077

Giovanni Corona, Linda Vignozzi, Giulia Rastrelli, Francesco Lotti, Sarah Cipriani, Mario Maggi. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions. Int J Endocrinol. 2014;2014:329456. doi: https://doi.org/10.1155/2014/329456

Čulić V. Androgens in cardiac fibrosis and other cardiovascular mechanisms. Int J Cardiol. 2015;179:190-2. doi: https://doi.org/10.1016/j.ijcard.2014.11.079

Stine A Holmboe, Tina K Jensen, Allan Linneberg, Thomas Scheike, Betina H Thuesen, Niels E Skakkebaek, Anders Juul, Anna-Maria Andersson. Low Testosterone: A Risk Marker Rather Than a Risk Factor for Type 2 Diabetes. J Clin Endocrinol Metabol. 2016;101(8):3180-90. doi: https://doi.org/10.1210/jc.2016-1778

Reddy YNV, Borlaug BA, O’Connor CM, Gersh BJ. Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. Eur Heart J 2020;41:1764-74. doi: https://doi.org/10.1093/eurheartj/ehz364

Kessler EL, Rivaud MR, Vos MA, Veen TAB. Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol Sex Differ. 2019;10(1):7. Published 2019 Feb 4. doi: https://doi.org/10.1186/s13293-019-0223-0

Putta VR, Chintakuntla N, Mallepally RR, Avudoddi SK, Nancherla D, et al. Synthesis and Eva¬luation of In Vitro DNA Protein Binding Affinity, Anti¬microbial, Antioxidant and Antitumor Activity of Mononu¬clear Ru(II) Mixed Polypyridyl Complexes. J Fluoresc. 2016;26(1):225-40. doi: https://doi.org/10.1007/s10895-015-1705-z

Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):68-72.

doi: https://doi.org/10.14797/mdcj-13-2-68

Gagliano-Jucá T, BasariaS. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16:555-74.

doi: https://doi.org/10.1038/s41569-019-0211-4

Fishman SL, Sonmez H, Basman C. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(59). doi: https://doi.org/10.1186/s10020-018-0060-3

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726. doi: https://doi.org/10.1093/eurheartj/ehab368